What's Going On With Tempus AI Stock Today? - Tempus AI (NASDAQ:TEM)

Core Insights - Tempus AI has introduced its new HRD-RNA algorithm, an AI-driven tool aimed at enhancing the detection of homologous recombination deficiency (HRD) in tumors, which has positively impacted its stock price [1][6] Product Development - The HRD-RNA algorithm analyzes gene expression to identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, providing a more dynamic assessment of tumor biology compared to traditional genomic methods [2] - A real-world validation study indicated that HRD-RNA–positive metastatic pancreatic cancer patients treated with first-line platinum-based regimens experienced a significant reduction in mortality risk compared to those receiving non-platinum therapies [2] - The company plans to make the HRD-RNA test clinically available later this year, offering physicians a functional view of HRD status by examining the transcriptome [3] Technical Analysis - The stock is currently trading 8.3% below its 20-day simple moving average (SMA) and 25.8% below its 100-day SMA, indicating a bearish trend [4] - Over the past 12 months, shares have decreased by 35.86%, positioning them closer to their 52-week lows [4] - The RSI is at 35.53, indicating neutral territory, while the MACD shows a value of -3.9401, below its signal line, suggesting bearish pressure [4][5] Analyst Outlook - Tempus AI is set to report earnings on February 24, 2026, with an EPS estimate of a loss of 13 cents, improved from a loss of 18 cents year-over-year [7][10] - Revenue estimates stand at $364.25 million, up from $200.68 million year-over-year [10] - The stock carries a Buy Rating with an average price target of $76.60, although recent analyst actions indicate mixed sentiments with some lowering their targets [8][10] Market Position - The company is positioned as a leader in precision medicine, leveraging AI to enhance treatment options and potentially improve patient outcomes [6] - Key resistance for the stock is identified at $61.50, while key support is at $50.00 [9] - Tempus AI shares were up 3.41% at $54.35 during premarket trading, reflecting some positive market activity [11]